Related references
Note: Only part of the references are listed.Inhibition of FLT3 in AML: a focus on sorafenib
A. Antar et al.
BONE MARROW TRANSPLANTATION (2017)
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
Jiang Chen et al.
ONCOTARGET (2016)
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade
Talha Badar et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
T-cell exhaustion in the tumor microenvironment
Y. Jiang et al.
CELL DEATH & DISEASE (2015)
Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Nestor R. Ramos et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Myeloid-derived suppressor cells as therapeutic target in hematological malignancies
Kim De Veirman et al.
FRONTIERS IN ONCOLOGY (2014)
Acute myeloid leukemia: 2013 update on risk-stratification and management
Elihu H. Estey
AMERICAN JOURNAL OF HEMATOLOGY (2013)
The mTOR pathway and integrating immune regulation
Stephen P. Cobbold
IMMUNOLOGY (2013)
mTORC1 couples immune signals and metabolic programming to establish Treg-cell function
Hu Zeng et al.
NATURE (2013)
Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
Salut Brunet et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment
Tiziana Grafone et al.
ONCOLOGY REVIEWS (2012)
Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids
Yasemin Sancak et al.
CELL (2010)
The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages
Justin P. Edwards et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2010)
Sorafenib - a small molecule with big promise?
Tamar Tadmor et al.
LEUKEMIA & LYMPHOMA (2010)
Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells
Weiming Ouyang et al.
NATURE IMMUNOLOGY (2010)
Reactivations of Cytomegalovirus, Human Herpes Virus 6, and Epstein-Barr Virus Differ with Respect to Risk Factors and Clinical Outcome after Hematopoietic Stem Cell Transplantation
E. Jaskula et al.
TRANSPLANTATION PROCEEDINGS (2010)
Management of relapse after allo-SCT for AML and the role of second transplantation
B. N. Savani et al.
BONE MARROW TRANSPLANTATION (2009)
The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications
T. Weichhart et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Potential role of sorafenib in the treatment of acute myeloid leukemia
Shahram Mori et al.
LEUKEMIA & LYMPHOMA (2008)
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006)
Danielle A. Murphy et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Low CXCR4 membrane expression on CD34+ cells characterizes cells mobilized to blood
D Dlubek et al.
BONE MARROW TRANSPLANTATION (2006)
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
N Boissel et al.
BLOOD (2005)
Risk assessment in patients with acute myeloid leukemia and a normal karyotype
M Bienz et al.
CLINICAL CANCER RESEARCH (2005)
Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth
PO Iversen et al.
BLOOD (2002)
Apoptosis of keratinocytes is associated with infiltration of CD8+ lymphocytes and accumulation of Ki67 antigen
A Klimczak et al.
BONE MARROW TRANSPLANTATION (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)